Top 10 global pharmaceutical companies' R&D expenses in 2018 Roche tops the list with over 11 billion U.S. dollars

At present, large pharmaceutical companies are still the absolute main force in drug R & D investment In 2018, the world's top 15 biopharmaceutical companies will spend more than $100 billion on new drug research and development for the first time Maybe that's why we saw more drugs approved by the US FDA last year than ever before (Note: in January 2019, the FDA drug approval and Research Center issued the annual report In the past year, FDA has approved 59 new drugs and 7 biological analogues.) The number of new drugs approved by the FDA in 2009-2018 (the picture is from the FDA website) is undeniably that the FDA has been overstocking and delaying the approval of some drugs since 2017, which is also a reason for the increase of the number of drugs approved in 2018 Earlier this year, a new report released by the iqvia Institute for human data science showed that in fact, the share of research and development of large pharmaceutical companies (companies with annual sales of more than $10 billion) has declined from 31% to just 20% in the past decade The report also found that small biotech companies spend more on innovative drugs than large pharmaceutical companies In 2018, we saw 59 new therapies approved by Dr Scott Gottlieb, former FDA director But less than half of the nearly 60 are from large pharmaceutical companies, according to the report On the other hand, 38 out of 59 treatments (64%) were founded by new biopharmaceutical companies The report also said that "the importance and investment of large pharmaceutical companies in R & D of new drugs is declining", but they are still important partners of emerging biotechnology companies Researchers say small biopharmaceutical companies still need to work with large pharmaceutical companies and their large sales teams "In the future, the industry ecology of development, M & A and licensing appears to be changing, and emerging companies are maintaining greater use and control of their assets," the report's authors wrote Related to this, according to the index, emerging biopharmaceutical companies (spending less than $200 million on R & D and less than $500 million in sales per year) account for 72% of all late product line pipeline activities, up from 61% a decade ago However, despite the proportion of investment, in terms of numerical value alone, companies such as Roche, J & J and Novartis still have no one to surpass in terms of R & D budget Last year, Roche again ranked the top with more than $11 billion in R & D expenses (including its diagnosis business) Over the years, the ranking of companies and the amount of investment have not changed much In fact, Roche has been in the leading position for several consecutive years since 2016, and its R & D expenditure has decreased by nearly 500 million, but there is a big exception Sanofi's R & D investment has increased by more than 1 billion US dollars in two years, from 5.45 billion US dollars in 2016 to 6.6 billion US dollars in 2018, because the company has signed a number of biotechnology transactions and M & A, and Sanofi is also In an attempt to return to the field of oncology that seemed to have been abandoned before Mosadon's investment in new drug research and development is also highly praised Although its R & D budget was down from last year (when it spent $10.33 billion), its total expenditure still reached $9.75 billion, second only to Novartis, which jumped from the fifth place in 2016 (with a total investment of $7.19 billion) to the third place, perhaps thanks to more than 1000 clinical trials of keytruda, the company's cancer star drug In short, as more drugs are approved and R & D investment gradually increases, people often think that the decisive role is the credit of those large pharmaceutical companies However, as the iqvia report found, more and more small emerging companies have played a more influential role in R & D investment, even surpassing large pharmaceutical companies in some areas Reference source: the top 10 Pharma R & D budget in 2018https://www.finebiotech.com/special-report/top-10-pharma-r-d-budget-2018